## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1. (currently amended) <u>Peptide nucleic Peptide nucleic</u> acid (PNA) comprising 12 to 24 nucleotide bases, said <u>peptide nucleic peptide nucleic</u> acid being complementary to the sense or antisense filament of human N-myc gene.
- 2. (currently amended) The peptide nucleic peptide nucleic acid (PNA) according to claim
- 1, in which antisense PNA (5'-TCCACCCAGCGCGTCC-3') is an only sequence complementary to 5'-UTR region of human N-myc gene.
- 3. (currently amended) The peptide nucleic peptide nucleic acid (PNA) according to claim
- 1, in which PNA is conjugated with a carrier that can get through the nuclear membrane of target cells expressing N-myc gene.
- 4. (currently amended) The conjugated <u>peptide nucleic-peptide nucleic-</u> acid (PNA) according to claim 3, in which said carrier is conjugated in 3' position to PNA sequence.
- 5. (currently amended) The peptide nucleic peptide nucleic acid (PNA) according to claim
- 3, in which said carrier is chosen among the following peptide sequences:

PKKKRKV;

RQIKIWFQNRRMKWKK;

GWTLNSAGYLLGKINLAALAKKIL;

(D)-KKWKMRRNQFWVKVQR;

GRKKRRQRRRPPQ;

YGRKKRRQRRR;

MSVLTPLLLRGLTGSARRLPVPRAKIHSL;

KFFKFFKFFK:

KKKK.

- 6. (currently amended) The peptide nucleicpeptide-nucleic- acid (PNA) according to claim
- 3, in which conjugated PNA is a sense <u>anti-geneantigen</u> PNA or an antisense <u>anti-geneantigen</u> PNA.
- 7. (currently amended) The peptide nucleic peptido-nucleic acid (PNA) according to claim

6, in which sense <u>anti-geneantigen</u> PNA or antisense <u>anti-geneantigen</u> PNA (5'-ATGCCGGCATGATCT-3'; antisense <u>anti-geneantigen</u>: 5'-AGATCATGCCCGGCAT-3') are complementary to a exonexone 2 sequence of N-myc gene.

8. (currently amended) The peptide nucleic peptido-nucleic acid (PNA) according to claim

3, in which sense anti-geneantigen PNA or antisense anti-geneantigen PNA are conjugated

in 3' with a nuclear localization signal (NLS) deriving from SV40 virus (peptide sequence

PKKKRKV).

9. (currently amended) A pharmaceutical composition comprising a <u>peptide nucleic</u><del>peptide</del>

nucleic- acid PNA according to claim 1.

10. (currently amended) A method to treat genetic diseases comprising the step of using a

peptide nucleic Use of a peptide nucleic acid PNA according to claim 1 for preparing a

pharmaceutical composition for treating genetic diseases.

11. (currently amended) The method Use of a peptido-nucleic acid PNA according to claim

10, wherein the genetic diseases are for preparing a pharmaceutical composition for treating

tumors associated to the expression of N-MYC protein.

12. (currently amended) The method Use of a peptido nucleic acid PNA according to claim

10, wherein the genetic diseases are for preparing a pharmaceutical composition for treating

tumors selected from the group consisting of such as neuroblastoma, retinoblastoma,

medulloblastoma, glioblastoma, astrocytoma or lung small cell tumor, rhabdomyosarcoma,

and B-type lymphoblastic acute leukemias.

13. (currently amended) The peptide nucleicpeptide nucleic acid (PNA) according to claim

4, in which said carrier is chosen among the following peptide sequences:

PKKKRKV;

RQIKIWFQNRRMKWKK:

GWTLNSAGYLLGKINLAALAKKIL:

(D)-KKWKMRRNQFWVKVQR;

GRKKRRQRRRPPQ:

YGRKKRRQRRR;

MSVLTPLLLRGLTGSARRLPVPRAKIHSL;

KFFKFFKFFK;

KKKK.

- 14. (currently amended) The <u>peptide nucleic-peptide nucleic-</u> acid (PNA) according to claim 4, in which conjugated PNA is a sense <u>anti-geneantigen</u> PNA or an antisense <u>anti-geneantigen</u> PNA.
- 15. (currently amended) The <u>peptide nucleic-peptide-nucleic-</u> acid (PNA) according to claim 5, in which conjugated PNA is a sense <u>anti-geneantigen</u> PNA or an antisense <u>anti-geneantigen</u> PNA.
- 16. (currently amended) The <u>peptide nucleic-peptide-nucleic-</u> acid (PNA) according to claim 14, in which sense <u>anti-geneantigen</u> PNA or antisense <u>anti-geneantigen</u> PNA (5'-ATGCCGGGCATGATCT-3'; antisense <u>anti-geneantigen</u>: 5'-AGATCATGCCCGGCAT-3') are complementary to a <u>exonexone</u> 2 sequence of N-myc gene.
- 17. (currently amended) The <u>peptide nucleic-peptide-nucleic-</u> acid (PNA) according to claim 15, in which sense <u>anti-geneantigen</u> PNA or antisense <u>anti-geneantigen</u> PNA (5'-ATGCCGGGCATGATCT-3'; antisense <u>anti-geneantigen</u>: 5'-AGATCATGCCCGGCAT-3') are complementary to a <u>exonexone</u> 2 sequence of N-myc gene.